Objectives:To develop the List of Clinical Needs for New Chinese Materia Medica Development(Second Batch),aiming to identify and highlight specific diseases with pressing,unmet therapeutic needs.The objective is to gu...Objectives:To develop the List of Clinical Needs for New Chinese Materia Medica Development(Second Batch),aiming to identify and highlight specific diseases with pressing,unmet therapeutic needs.The objective is to guide pharmaceutical research and development(R&D)by establishing development priorities based on clinical gaps,epidemiological burden,and the shortcomings of existing treatments.Methods:The list was developed by the China Association of Chinese Medicine using a methodology grounded in evidence and expert consensus.Results:The list identifies 8 diseases with significant clinical gaps:Myelodysplastic syndromes(MDS),fibromyalgia(FM),atrophic gastritis and its precancerous lesions,adenomyosis(AM),diabetes related foot ulcers(DFU),granulomatous mastitis(GLM),diabetic kidney disease(DKD),and metabolic-associated fatty liver disease(MAFLD).For each disease,the list provides a systematic analysis of epidemiological burden,limitations of current treatments,and specific clinical needs.It also proposes a strategic research framework focused on multi-target mechanisms,disease-modifying potential,and optimized combination therapies.Conclusions:The list provides a strategically structured framework to guide the development of new Chinese materia medica.It aligns traditional Chinese medicine(TCM)development with national public health priorities,emphasizes TCM's holistic and multi-target advantages,and promotes a patient-centered approach.By bridging clinical needs with TCM principles,the list aims to foster the creation of clinically valuable medicines to address chronic and complex diseases where current western medical approaches are insufficient.展开更多
文摘目的以"原位再生医疗技术治疗糖尿病足"(MEBO-DFU)的规范化流程作为临床应用研究基础,对MEBO-DFU原位再生终止截肢关键节点(Key Nodes,KN)的机制进行辨析,为临床应用理清思路。方法临床总结发现,每个MEBO-DFU规范应用原位再生医疗技术治疗的关键节点都是在对应关键控制点(Critical Control Point,CCP)的掌控下实施的,关键节点的相互连接保障了原位再生医疗技术的临床效果,终止了DFU的截肢手术,实现了创面的原位再生愈合。结果 MEBO-DFU为创面的原位再生创造了生理生态条件,通过溃疡创面的原位再生保留了已坏死的肢、趾,且复发率低,这些效果决定于各个关键节点的正确掌控与实施。结论把握好MEBO-DFU终止截肢的关键节点和与之对应的关键控制点,既是严格规范的原位再生医疗技术实现MEBO-DFU终止截肢与创面原位再生的基础,也是MEBO-DFU规范应用、保障疗效、制定可行治疗规范程序的依据。
文摘Objectives:To develop the List of Clinical Needs for New Chinese Materia Medica Development(Second Batch),aiming to identify and highlight specific diseases with pressing,unmet therapeutic needs.The objective is to guide pharmaceutical research and development(R&D)by establishing development priorities based on clinical gaps,epidemiological burden,and the shortcomings of existing treatments.Methods:The list was developed by the China Association of Chinese Medicine using a methodology grounded in evidence and expert consensus.Results:The list identifies 8 diseases with significant clinical gaps:Myelodysplastic syndromes(MDS),fibromyalgia(FM),atrophic gastritis and its precancerous lesions,adenomyosis(AM),diabetes related foot ulcers(DFU),granulomatous mastitis(GLM),diabetic kidney disease(DKD),and metabolic-associated fatty liver disease(MAFLD).For each disease,the list provides a systematic analysis of epidemiological burden,limitations of current treatments,and specific clinical needs.It also proposes a strategic research framework focused on multi-target mechanisms,disease-modifying potential,and optimized combination therapies.Conclusions:The list provides a strategically structured framework to guide the development of new Chinese materia medica.It aligns traditional Chinese medicine(TCM)development with national public health priorities,emphasizes TCM's holistic and multi-target advantages,and promotes a patient-centered approach.By bridging clinical needs with TCM principles,the list aims to foster the creation of clinically valuable medicines to address chronic and complex diseases where current western medical approaches are insufficient.
